1. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). (January 2020) Authors: Mascarenhas, J.; Marcellino, B.K.; Lu, M.; Kremyanskaya, M.; Fabris, F.; Sandy, L.; Mehrotra, M.; Houldsworth, J.; Najfeld, V.; El Jamal, S.; Petersen, B.; Moshier, E.; Hoffman, R. Journal: Leukemia research Issue: Volume 88(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. To evaluate P-glycoprotein expression in relation to molecular subtypes and predicting response to neoadjuvant chemotherapy in breast cancer – a study from a tertiary care center in India. (February 2017) Authors: Mehrotra, M.; Sonkar, A.A.; Anand, A.; Husain, N. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: T-CELL RECEPTOR SEQUENCING AND T-CELL MONOCLONALITY: A NOVEL BIOMARKER OF RESPONSE TO IVIG IN MDS PATIENTS WITH AUTOIMMUNE CYTOPENIAS. (September 2021) Authors: Feld, J.; Houldsworth, J.; Reddy, A.; Mai, Z.; Hussein, S.; Navada, S.; Silverman, L.; Mehrotra, M. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗